Tagged with Biotech,

Hong Kong Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious career in the US to bring in novel technologies to the city.   I feel happy that I have achieved my initial objectives: to bring international…

Turkey Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares his experience working for the largest biotech in the MENA region, Turkey’s important role within the global group, and his ambitious plans for the future.   “Having worked for leading Turkish companies for several years … I realized that…

Singapore Vishal Doshi, founder and CEO of AUM Biosciences, shares his motivation behind establishing the company and his mission to build an ecosystem within AUM for a decentralized biotech innovation model; their focus on oncology and specifically small molecule cancer therapies; and the critical importance of the China market within their…

China Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary (GU) tumours and related disease because of the significant and oft-overlooked medical needs there; and the importance of building and…

China Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization), and their exciting international clinical development strategy for their three assets.   I realized that if I wanted to establish…

China China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve the unmet needs of patients with their cutting-edge technologies in cardiology, immunology and more.   Adagene Adagene’s founder and CEO…

China Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO in 2008, before launching a new ‘equity-for-service’ model in 2016 that focused on incubating biotech start-ups from their inception to IND stage. He highlights their…

China Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which recently concluded Phase III trials in China; and their future plans for an IPO.   We combined US experience and…

Sweden Ascelia Pharma is a Swedish oncology start-up based in Malmö. CEO Magnus Corfitzen talks about the opportunities they have found in the orphan oncology drug market, the promising phase III study for their lead asset, Mangoral, and his journey navigating the Swedish life science industry.   With Mangoral, we are…

Taiwan Tessie Che, chairperson & GM of Amaran Biotech shares the story of how she came to lead the company and set its course to become a leading specialty biopharma CMO that leverages high-quality products and best manufacturing practices above all else. As a veteran in the life sciences and pharma…

USA Although Boston and California may be more internationally renowned as biotech hubs, New York is fast catching up. Thanks in large part to its strong scientific and business infrastructure and easy access to capital, growing numbers of early-stage biotechs are choosing to base their operations in New York and list…

Korea The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how.   Once we chose to specialise in biosimilars, there was no room to survive if we failed with the few projects…